Apimeds Pharmaceuticals Files Q2 2025 10-Q
Ticker: APUS · Form: 10-Q · Filed: Aug 19, 2025 · CIK: 1894525
| Field | Detail |
|---|---|
| Company | Apimeds Pharmaceuticals Us, INC. (APUS) |
| Form Type | 10-Q |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01, $1,599,060 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
APIMEDS PHARMA 10-Q FILED FOR Q2 2025. CHECK FINANCIALS.
AI Summary
Apimeds Pharmaceuticals US, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2025. The company, incorporated in Delaware with its principal executive offices in Matawan, New Jersey, operates in the Pharmaceutical Preparations industry. The filing was made on August 19, 2025, under SEC file number 001-42545.
Why It Matters
This filing provides investors with an update on Apimeds Pharmaceuticals' financial performance and operational status for the second quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine quarterly filing and does not contain immediate, high-impact news.
Key Players & Entities
- Apimeds Pharmaceuticals US, Inc. (company) — Registrant
- June 30, 2025 (date) — Quarterly period end date
- August 19, 2025 (date) — Filing date
- 001-42545 (other) — SEC File Number
- Matawan, New Jersey (location) — Principal executive offices
FAQ
What is the primary business of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
When was the quarterly period covered by this 10-Q filing?
The quarterly period ended on June 30, 2025.
What is the SEC file number for Apimeds Pharmaceuticals US, Inc.?
The SEC file number is 001-42545.
Where are the principal executive offices of Apimeds Pharmaceuticals US, Inc. located?
The principal executive offices are located at 100 Matawan Rd, Suite 325, Matawan, New Jersey, 07747.
On what date was this 10-Q form filed with the SEC?
This 10-Q form was filed on August 19, 2025.
Filing Stats: 4,600 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2025-08-19 16:18:43
Key Financial Figures
- $0.01 — ich registered Common stock, par value $0.01 per share APUS NYSE American LLC Indi
- $1,599,060 — Issuance of common stock in IPO (net of $1,599,060 in offering costs and warrant liability
Filing Documents
- ea0251232-10q_apimeds.htm (10-Q) — 535KB
- ea025123201ex10-1_apimeds.htm (EX-10.1) — 5KB
- ea025123201ex10-2_apimeds.htm (EX-10.2) — 6KB
- ea025123201ex10-3_apimeds.htm (EX-10.3) — 6KB
- ea025123201ex31-1_apimeds.htm (EX-31.1) — 9KB
- ea025123201ex31-2_apimeds.htm (EX-31.2) — 9KB
- ea025123201ex32-1_apimeds.htm (EX-32.1) — 3KB
- ea025123201ex32-2_apimeds.htm (EX-32.2) — 3KB
- 0001213900-25-078507.txt ( ) — 3955KB
- apus-20250630.xsd (EX-101.SCH) — 33KB
- apus-20250630_cal.xml (EX-101.CAL) — 23KB
- apus-20250630_def.xml (EX-101.DEF) — 180KB
- apus-20250630_lab.xml (EX-101.LAB) — 338KB
- apus-20250630_pre.xml (EX-101.PRE) — 193KB
- ea0251232-10q_apimeds_htm.xml (XML) — 395KB
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION 1
Financial Statements
Item 1. Financial Statements 1
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 25
Controls and Procedures
Item 4. Controls and Procedures 25
—OTHER INFORMATION
PART II—OTHER INFORMATION 27
Legal Proceedings
Item 1. Legal Proceedings 27
Risk Factors
Item 1A. Risk Factors 27
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 27
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 27
Other Information
Item 5. Other Information 27
Exhibits
Item 6. Exhibits 28
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. INDEX TO FINANCIAL STATEMENTS Contents Page Unaudited Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 2 Unaudited Condensed Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 3 Unaudited Condensed Statements of Changes in Shareholders' Equity (Deficit) for the Three and Six Months Ended June 30, 2025 and 2024 4 Unaudited Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 5 Notes to Unaudited Condensed Financial Statements 6 1 Apimeds Pharmaceuticals US, Inc. Unaudited Condensed Balance Sheets June 30, December 31, 2025 2024 Assets Current assets: Cash $ 8,735,323 $ 3,455 Prepaid expenses and other current assets 1,614,226 9,602 Total current assets 10,349,549 13,057 Property and equipment, net 13,137 - Long-term portion of prepaid expenses 183,995 - Total assets $ 10,546,681 $ 13,057 Liabilities and shareholders' equity Current liabilities: Accounts payable and accrued expenses $ 119,138 $ 591,191 Accrued interest - related party 15,351 106,643 Advance payable to related party 100 76,500 Notes payable - related party 500,000 250,000 Warrant Liability 174,413 - Total current liabilities 809,002 1,024,334 Long-term liabilities Long-term convertible notes payable – Related Party - 346,844 Total liabilities $ 809,002 $ 1,371,178 Commitments and contingencies (note 8) - - Shareholders' Equity: Preferred stock, par value $ 0.01 , 10,000,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024 $ - $ - Common stock, par value $ 0.01 , 100,000,000 shares authorized; 12,575,983 and 7,903,850 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 125,760 79,039 Additional paid-in capital 17,068,433 2,954,764 Accumulated deficit ( 7,456,514 ) ( 4,391,924 ) Total shareholders' equity (defic